EP4311577A3 - Composés inhibiteurs de métalloenzymes - Google Patents

Composés inhibiteurs de métalloenzymes Download PDF

Info

Publication number
EP4311577A3
EP4311577A3 EP23212447.9A EP23212447A EP4311577A3 EP 4311577 A3 EP4311577 A3 EP 4311577A3 EP 23212447 A EP23212447 A EP 23212447A EP 4311577 A3 EP4311577 A3 EP 4311577A3
Authority
EP
European Patent Office
Prior art keywords
inhibitor compounds
metalloenzyme inhibitor
metalloenzyme
compounds
metalloenzymes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23212447.9A
Other languages
German (de)
English (en)
Other versions
EP4311577A2 (fr
Inventor
Steven SPARKS
Christopher M. Yates
Sammy Shaver
William J. Hoekstra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ji Xing Pharmaceuticals Hong Kong Ltd
Original Assignee
Ji Xing Pharmaceuticals Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ji Xing Pharmaceuticals Hong Kong Ltd filed Critical Ji Xing Pharmaceuticals Hong Kong Ltd
Publication of EP4311577A2 publication Critical patent/EP4311577A2/fr
Publication of EP4311577A3 publication Critical patent/EP4311577A3/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP23212447.9A 2016-12-29 2017-12-22 Composés inhibiteurs de métalloenzymes Pending EP4311577A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29
PCT/US2017/068190 WO2018125800A2 (fr) 2016-12-29 2017-12-22 Composés inhibiteurs des métalloenzymes
EP17887556.3A EP3562487B1 (fr) 2016-12-29 2017-12-22 Composés inhibiteurs des métalloenzymes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP17887556.3A Division EP3562487B1 (fr) 2016-12-29 2017-12-22 Composés inhibiteurs des métalloenzymes

Publications (2)

Publication Number Publication Date
EP4311577A2 EP4311577A2 (fr) 2024-01-31
EP4311577A3 true EP4311577A3 (fr) 2024-04-17

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23212447.9A Pending EP4311577A3 (fr) 2016-12-29 2017-12-22 Composés inhibiteurs de métalloenzymes
EP17887556.3A Active EP3562487B1 (fr) 2016-12-29 2017-12-22 Composés inhibiteurs des métalloenzymes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17887556.3A Active EP3562487B1 (fr) 2016-12-29 2017-12-22 Composés inhibiteurs des métalloenzymes

Country Status (15)

Country Link
US (3) US10085984B2 (fr)
EP (2) EP4311577A3 (fr)
JP (2) JP7227157B2 (fr)
KR (1) KR102690885B1 (fr)
CN (1) CN110691598A (fr)
AU (2) AU2017387033B2 (fr)
BR (1) BR112019013478A2 (fr)
CA (1) CA3055292A1 (fr)
DK (1) DK3562487T3 (fr)
ES (1) ES2967119T3 (fr)
FI (1) FI3562487T3 (fr)
MX (2) MX2019007892A (fr)
RU (1) RU2764666C2 (fr)
TW (1) TWI786078B (fr)
WO (1) WO2018125800A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102061137B1 (ko) * 2012-01-20 2019-12-31 마이코비아 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
WO2018125799A2 (fr) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Composés inhibiteurs des métalloenzymes
EP3908319B1 (fr) * 2019-01-08 2023-10-18 Ji Xing Pharmaceuticals Hong Kong Limited Composés inhibiteurs de métalloenzyme
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
BR112022023550A2 (pt) 2020-05-19 2023-01-03 Bayer Cropscience Ag (tio)amidas azabicíclicas como compostos fungicidas
US20230234945A1 (en) 2020-06-10 2023-07-27 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156462A2 (fr) * 2008-06-27 2009-12-30 Novartis Ag Composés organiques
WO2012012478A1 (fr) * 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Inhibiteurs de l'aldostérone synthase

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DE69009946T2 (de) 1989-12-04 1994-11-03 Searle & Co System zur transdermalen Albuterol Applikation.
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ マイニング アンド マニュファクチャリング カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1474425B9 (fr) * 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines et leurs utilisations
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
EP1604988A1 (fr) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques
KR101099303B1 (ko) 2005-01-28 2011-12-26 주식회사 대웅제약 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (fr) 2006-07-15 2008-01-16 sanofi-aventis Synthèse régiosélective des benzimidazoles et azabenzimidazoles catalysée par le palladium
JP2010524892A (ja) 2007-04-19 2010-07-22 ノバルティス アーゲー 代謝型グルタミン酸受容体−5の修飾因子としてのニコチン酸誘導体
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
CA2701115A1 (fr) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Composes n-hydroxy-naphtalene dicarboxamide et n-hydroxy-biphenyl-dicarboxamide comme inhibiteurs de l'histone desacetylase
EP2254572B1 (fr) 2008-02-07 2013-10-16 Massachusetts Eye & Ear Infirmary Composés stimulant l expression du gène atoh-1
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
EP2993169B1 (fr) 2009-11-17 2017-12-20 Novartis AG Dérivés de l'arylpyridine comme inhibiteurs de l'aldosterone synthase
WO2012045804A1 (fr) 2010-10-08 2012-04-12 Vib Vzw Inhibiteurs des hdac pour traiter l'amyotrophie péronière de charcot-marie-tooth
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
WO2013033901A1 (fr) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
WO2014179303A1 (fr) 2013-04-29 2014-11-06 The General Hospital Corporation Bloqueurs de l'arn messager de protéine précurseur de l'amyloïde permettant de traiter le syndrome de down et la maladie d'alzheimer
MY176401A (en) 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (fr) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
EP3558984B1 (fr) 2016-12-20 2023-08-02 FMC Corporation Oxadiazoles à activité fongicide
WO2018125799A2 (fr) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Composés inhibiteurs des métalloenzymes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156462A2 (fr) * 2008-06-27 2009-12-30 Novartis Ag Composés organiques
WO2012012478A1 (fr) * 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Inhibiteurs de l'aldostérone synthase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GÖKER, H. ET AL.: "Synthesis and potent antifungal activity against Candida species of some novel 1H-benzimidazoles", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 46, no. 5, 2009, pages 936 - 948, XP002596734, ISSN: 0022-152X, DOI: 10.1002/JHET.179 *
HOYT, S.B. ET AL.: "Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 5, 2015, pages 573 - 578, XP055534685, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.5b00054 *
MEREDITH, E.L. ET AL.: "Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors", ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 12, 2013, pages 1203 - 1207, XP002755995, ISSN: 1948-5875, [retrieved on 20131017], DOI: 10.1021/ML400324C *
PAPILLON, J.P.N. ET AL.: "Discovery of N -[5-(6-Chloro-3-cyano-1-methyl-1 H -indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 23, 2015, pages 9382 - 9394, XP055715085, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01545 *

Also Published As

Publication number Publication date
RU2764666C2 (ru) 2022-01-19
MX2019007892A (es) 2020-02-05
BR112019013478A2 (pt) 2020-01-07
JP2020510693A (ja) 2020-04-09
JP7227157B2 (ja) 2023-02-21
KR102690885B1 (ko) 2024-08-02
US20210322409A1 (en) 2021-10-21
EP3562487A2 (fr) 2019-11-06
AU2017387033B2 (en) 2024-02-01
CN110691598A (zh) 2020-01-14
TWI786078B (zh) 2022-12-11
EP4311577A2 (fr) 2024-01-31
RU2019123854A3 (fr) 2021-05-12
MX2022012386A (es) 2022-11-30
DK3562487T3 (da) 2024-01-02
TW201831465A (zh) 2018-09-01
FI3562487T3 (fi) 2023-12-14
KR20190129034A (ko) 2019-11-19
EP3562487B1 (fr) 2023-11-29
US20190008861A1 (en) 2019-01-10
EP3562487A4 (fr) 2020-08-26
AU2017387033A1 (en) 2019-08-15
WO2018125800A2 (fr) 2018-07-05
US20180185362A1 (en) 2018-07-05
ES2967119T3 (es) 2024-04-26
US11040034B2 (en) 2021-06-22
CA3055292A1 (fr) 2018-07-05
JP2023071692A (ja) 2023-05-23
AU2024202860A1 (en) 2024-05-23
RU2019123854A (ru) 2021-02-01
WO2018125800A3 (fr) 2018-08-16
US10085984B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
WO2011133875A3 (fr) Composés inhibiteurs de métalloenzyme
WO2012177603A3 (fr) Composés inhibiteurs de métalloenzymes
EP4311577A3 (fr) Composés inhibiteurs de métalloenzymes
MX2013015158A (es) Compuestos inhibidores de metaloenzima.
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
IN2014DN00286A (fr)
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2012064943A3 (fr) Composés inhibiteurs de métalloenzymes
IN2014DN06792A (fr)
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
WO2016172658A3 (fr) Régulateurs du microbiome et leurs utilisations associées
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
WO2011082245A3 (fr) Composés inhibiteurs de métallo-enzyme
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
WO2015200790A3 (fr) Compositions et procédés pour réguler la rénalase dans le traitement de certaines maladies et de certains troubles
WO2017139697A8 (fr) Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
WO2016200614A3 (fr) Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie
WO2012058529A3 (fr) Composés inhibiteurs de métalloenzymes
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
WO2020021480A3 (fr) Compositions et procédés de traitement de l'œil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3562487

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOEKSTRA, WILLIAM J.

Inventor name: SHAVER, SAMMY

Inventor name: YATES, CHRISTOPHER M.

Inventor name: SPARKS, STEVEN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0035000000

Ipc: C07D0403040000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240311BHEP

Ipc: A61P 3/00 20060101ALI20240311BHEP

Ipc: A61P 1/00 20060101ALI20240311BHEP

Ipc: A61K 31/501 20060101ALI20240311BHEP

Ipc: A61K 31/437 20060101ALI20240311BHEP

Ipc: C07D 417/14 20060101ALI20240311BHEP

Ipc: C07D 471/04 20060101ALI20240311BHEP

Ipc: C07D 405/14 20060101ALI20240311BHEP

Ipc: C07D 401/14 20060101ALI20240311BHEP

Ipc: C07D 403/14 20060101ALI20240311BHEP

Ipc: C07D 403/04 20060101AFI20240311BHEP

Ipc: A61P 9/00 20060101ALI20240311BHEP

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR